Episode 4: Highlights of the ESC cardio-oncology guidelines - New data in renal denervation: SYMPLICITY HTN-3

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

• Cardiology This Week: A concise summary of recent trials
• Highlights of the ESC Cardio Oncology Guidelines
• New Data in Renal Denervation: SYMPLICITY HTN-3
• Mythbusters: Coffee increases the risk for heart disease

Host: Rick Grobbee Guests: Carlos Aguiar, Teresa Lopez Fernandez and Deepak Bhatt

Want to watch that episode? Go to: https://esc365.escardio.org/event/607

Disclaimer: This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Teresa Lopez Fernandez declared to have no potential conflict of interest to report.

Carlos Aguiar declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Deepak Bhatt declared to have potential conflicts of interest to report: Research funding from Medtronic paid to Brigham and Women’s hospital for my role as co-Principal Investigator of SYMPLICITY HTN-3.

Davide Capodanno declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.

Emma Svennberg declared to have potential conflicts of interest to report: Institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme